Inmune Bio, Inc. 8-K

What Happened

• Inmune Bio, Inc. (INMB) announced in an 8-K filed June 17, 2026 that its stockholders approved the Third Amended and Restated 2021 Stock Incentive Plan at the company’s annual meeting. The amendment increases the number of shares issuable under the plan from 6,500,000 to 9,158,525 and adds an evergreen provision for future automatic increases.
• The evergreen provision will operate on the first trading day of each calendar year from 2027 through 2031, increasing the shares reserved under the plan by the lesser of (A) 10.0% of the company’s common stock outstanding on December 31 of the prior year, or (B) a smaller number as determined by the board. The full amended plan text was filed as Exhibit 10.1 to the 8-K.

Key Details

• Shares under plan increased from 6,500,000 to 9,158,525 (an increase of 2,658,525 shares).
• Evergreen increases effective first trading day of each year 2027–2031 by up to 10.0% of outstanding shares (or a smaller board-determined amount).
• Amended Plan had previously been approved by the board and was described in the company’s Definitive Proxy Statement filed April 23, 2026.

Why It Matters

• For investors, this decision authorizes a materially larger pool of shares for employee and other equity awards, which can dilute existing shareholders if awards are issued.
• The evergreen feature allows the share reserve to grow automatically (subject to limits), potentially increasing outstanding share count over the next several years and affecting metrics like earnings per share and ownership percentages.
• The amendment is a governance/compensation action—not an operational or financial results disclosure—so investors should monitor future grant activity and any related impacts on share count and compensation expense.